Immunophenotypic comparison of testicular sclerosing Sertoli cell tumors and Sertoli cell tumors not otherwise specified

Hum Pathol. 2017 Oct:68:99-102. doi: 10.1016/j.humpath.2017.08.022. Epub 2017 Sep 2.


Testicular Sertoli cell tumors (SCTs) are rare, and most fall into the category of SCT-not otherwise specified (SCT-NOS). Only a few additional types of SCT are recognized. Sclerosing SCT (S-SCT), originally described in 1991, comprises a small fraction of SCTs and was considered a specific entity until the 2016 revision of the World Health Organization classification of non-germ cell tumors, where it was classified as a morphologic variant of SCT-NOS. In a recent study, differences in expression of PAX2/PAX8, inhibin, androgen receptor, and S100 protein between SCT-NOS and S-SCT were noted in a small number of cases. In this interinstitutional study, we compared the expression of these markers and β-catenin in 11 cases each of SCT-NOS and S-SCT to determine if differences exist that could justify keeping a separate classification of these neoplasms. PAX2/PAX8 cocktail was the only marker that was significantly overexpressed in S-SCT. Expression of androgen receptors was strong in S-SCT and variable in SCT-NOS but did not reach statistical significance. Expression of β-catenin was common in both, whereas inhibin was infrequent. The available material was insufficient for a conclusive evaluation of S100 protein expression. Overall, our results support the inclusion of S-SCT as a morphologic variant of SCT-NOS. Expression of PAX2/PAX8 in S-SCT may reflect an overactive epithelial-to-mesenchymal transition as has been shown in experimental models of acute and chronic seminiferous tubular injury and might be related to the process generating the stroma in these tumors.

Keywords: Immunohistochemistry; PAX8 and PAX2; Receptors, androgen; Sertoli cells; Testicular neoplasms; β-Catenin.

Publication types

  • Multicenter Study

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Biopsy
  • Diagnosis, Differential
  • Humans
  • Immunohistochemistry*
  • Indiana
  • Inhibins / analysis
  • Male
  • Minnesota
  • PAX2 Transcription Factor / analysis*
  • PAX8 Transcription Factor / analysis*
  • Phenotype
  • Predictive Value of Tests
  • Prognosis
  • Receptors, Androgen / analysis
  • S100 Proteins / analysis
  • Sclerosis
  • Sertoli Cell Tumor / chemistry*
  • Sertoli Cell Tumor / pathology
  • Testicular Neoplasms / chemistry*
  • Testicular Neoplasms / pathology
  • beta Catenin / analysis


  • AR protein, human
  • Biomarkers, Tumor
  • CTNNB1 protein, human
  • PAX2 Transcription Factor
  • PAX2 protein, human
  • PAX8 Transcription Factor
  • PAX8 protein, human
  • Receptors, Androgen
  • S100 Proteins
  • beta Catenin
  • inhibin A
  • Inhibins